Header Logo

Connection

CATHY ENG to Antineoplastic Combined Chemotherapy Protocols

Back to Details
This is a "connection" page, showing publications CATHY ENG has written about Antineoplastic Combined Chemotherapy Protocols.
CATHY ENG
Connection Strength
2.419
Antineoplastic Combined Chemotherapy Protocols
  1. Pharmacotherapeutic considerations for elderly patients with colorectal cancer. Expert Opin Pharmacother. 2019 Dec; 20(17):2139-2160.
    View in: PubMed
    Score: 0.148
  2. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clin Colorectal Cancer. 2019 12; 18(4):301-306.
    View in: PubMed
    Score: 0.147
  3. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.
    View in: PubMed
    Score: 0.145
  4. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int J Cancer. 2016 Jul 01; 139(1):177-86.
    View in: PubMed
    Score: 0.117
  5. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84.
    View in: PubMed
    Score: 0.108
  6. Cetuximab in refractory squamous cell carcinoma of the anal canal. J Gastrointest Cancer. 2014 Dec; 45 Suppl 1:198-200.
    View in: PubMed
    Score: 0.107
  7. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014 Nov 30; 5(22):11133-42.
    View in: PubMed
    Score: 0.107
  8. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget. 2014 Aug 30; 5(16):6584-93.
    View in: PubMed
    Score: 0.105
  9. Will PICCOLO affect metastatic colorectal cancer therapy? Lancet Oncol. 2013 Jul; 14(8):679-80.
    View in: PubMed
    Score: 0.096
  10. Carcinoma of the anal canal: small steps in treatment advances. Clin Adv Hematol Oncol. 2011 Sep; 9(9):662-9.
    View in: PubMed
    Score: 0.085
  11. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther. 2011 Jul; 11(7):937-49.
    View in: PubMed
    Score: 0.084
  12. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010 Jan 15; 116(2):316-22.
    View in: PubMed
    Score: 0.076
  13. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):207-18.
    View in: PubMed
    Score: 0.072
  14. Emerging drugs for colorectal cancer. Expert Opin Emerg Drugs. 2008 Dec; 13(4):629-42.
    View in: PubMed
    Score: 0.071
  15. Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. Clin Colorectal Cancer. 2007 Oct; 6 Suppl 2:S53-9.
    View in: PubMed
    Score: 0.065
  16. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. Clin Adv Hematol Oncol. 2007 Jan; 5(1 Suppl 1):4-7.
    View in: PubMed
    Score: 0.062
  17. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023 01 20; 41(3):678-700.
    View in: PubMed
    Score: 0.046
  18. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020 08 01; 38(22):2510-2518.
    View in: PubMed
    Score: 0.039
  19. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.
    View in: PubMed
    Score: 0.039
  20. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol. 2017 Sep; 24(9):2646-2654.
    View in: PubMed
    Score: 0.032
  21. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017 05 15; 17(1):331.
    View in: PubMed
    Score: 0.032
  22. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11; 7(41):67495-67506.
    View in: PubMed
    Score: 0.030
  23. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist. 2015 Mar; 20(3):e3-4.
    View in: PubMed
    Score: 0.027
  24. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.026
  25. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 2014 Aug 15; 20(16):4240-50.
    View in: PubMed
    Score: 0.026
  26. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014 Jun; 109(7):740-5.
    View in: PubMed
    Score: 0.025
  27. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014 May; 22(5):1223-31.
    View in: PubMed
    Score: 0.025
  28. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.
    View in: PubMed
    Score: 0.025
  29. The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol. 2011 Aug 09; 8(11):649-59.
    View in: PubMed
    Score: 0.021
  30. Multidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer. Am J Clin Oncol. 2011 Aug; 34(4):411-6.
    View in: PubMed
    Score: 0.021
  31. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012 Mar; 23(3):652-658.
    View in: PubMed
    Score: 0.021
  32. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer. 2011 Sep; 10(3):198-202.
    View in: PubMed
    Score: 0.021
  33. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94.
    View in: PubMed
    Score: 0.020
  34. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist. 2010; 15(1):73-84.
    View in: PubMed
    Score: 0.019
  35. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
    View in: PubMed
    Score: 0.019
  36. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008 Dec; 9(4-6):400-7.
    View in: PubMed
    Score: 0.018
  37. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83.
    View in: PubMed
    Score: 0.018
  38. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.
    View in: PubMed
    Score: 0.018
  39. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.
    View in: PubMed
    Score: 0.018
  40. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
    View in: PubMed
    Score: 0.017
  41. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10; 26(14):2311-9.
    View in: PubMed
    Score: 0.017
  42. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9.
    View in: PubMed
    Score: 0.017
  43. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer. 2008 Jan; 7(1):65-8.
    View in: PubMed
    Score: 0.017
  44. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007 Dec 15; 110(12):2761-7.
    View in: PubMed
    Score: 0.016
  45. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer. 2006 May 15; 106(10):2241-6.
    View in: PubMed
    Score: 0.015
  46. The treatment of colorectal carcinoma: standard chemotherapy and beyond. Clin Adv Hematol Oncol. 2004 Sep; 2(9):592-8.
    View in: PubMed
    Score: 0.013
  47. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol. 2004 Jun; 15(6):928-32.
    View in: PubMed
    Score: 0.013
  48. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 07 01; 402(10395):41-53.
    View in: PubMed
    Score: 0.012
  49. The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. Curr Treat Options Oncol. 2022 08; 23(8):1073-1085.
    View in: PubMed
    Score: 0.011
  50. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47.
    View in: PubMed
    Score: 0.011
  51. Current treatment and future directions in the management of anal cancer. CA Cancer J Clin. 2022 03; 72(2):183-195.
    View in: PubMed
    Score: 0.011
  52. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist. 2021 02; 26(2):e261-e269.
    View in: PubMed
    Score: 0.010
  53. Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. J Natl Compr Canc Netw. 2020 07; 18(7):798-804.
    View in: PubMed
    Score: 0.010
  54. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.009
  55. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018 06; 67(6):1095-1102.
    View in: PubMed
    Score: 0.008
  56. Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection. Ann Surg Oncol. 2017 Sep; 24(9):2595.
    View in: PubMed
    Score: 0.008
  57. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154.
    View in: PubMed
    Score: 0.008
  58. Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May; 8(5):623-33.
    View in: PubMed
    Score: 0.006
  59. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010 Apr; 55(4):1098-105.
    View in: PubMed
    Score: 0.005
  60. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008 Mar; 19(3):577-82.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.